PRKN and prostate carcinoma: In conclusion, our study elucidates that GRh2 targets prostate cancer by inducing mitochondrial damage, which subsequently activates two critical pathways: PINK1/Parkin-mediated mitophagy and ferroptosis (Figure 6).